APLIF - Appili Therapeutics' favipiravir fails main goal in late-stage COVID-19 trial

Appili Therapeutics (OTCQX:APLIF) announces that the company's oral antiviral Avigan/Reeqonus (favipiravir) failed to meet the primary endpoint in a late-stage trial for the treatment of mild-to-moderate COVID-19. The Phase 3 PRESECO (PREventing SEvere COVID-19 Disease) study is a double-blind, placebo-controlled, randomized, multi-center, global superiority trial investigating the safety and efficacy of oral Avigan/Reeqonus in the early treatment for adults infected with COVID-19 and showing mild-to-moderate symptoms. Participants were enrolled at multiple clinical trial sites in the United States, Brazil and Mexico. The company highlighted that additional analyses of the trial data are ongoing.

For further details see:

Appili Therapeutics' favipiravir fails main goal in late-stage COVID-19 trial